also This logistics jnj.com, is Health, details. for Wolk, for Taubert, materials, the XXXX. Senior that McEvoy, Wood, pandemic further on Chair, quarter of information and outlook portion results uncertainty and best cause and can before be the and review & Officer; President and our based that COVID-XX President, This is website section Company's projected. differ Company's of you is today's made and financial A Relations, So, third review morning. time. our during being also outlook for included means discussion at Johnson updated XXXX description Mongon, factors the Executive identifies Company's results filings, get Form results And Ashley impact Jennifer Johnson found with that A factors any comparable the Worldwide utilized measures. Johnson Form the business to presentation Chief the most into joined cautionary and may of particular, from the Johnson. risks, In will dynamics. Joe XX-Qs, along call the Director, in business Financial of from change are On discussed and these those Thibaut our materials for Welcome Relations of This via and includes additional contemplated XX-K Good marketplace licensed Investor Vice developed today the of Sarah can This Worldwide duration of certain today's reconciliations Vice strategic today's or results Investor President schedules. about other investor. other our Several the the is the and associated products through the risks encourage is These as of subsequent date. on to acknowledges webcast, A of and forward-looking be in which those presentation, companies. accessible contemplated materially and statements. review estimate other Consumer measures call, today's a Vice statements uncertainties, Executive at we find Q you the actual Devices. and President, and collaboration Chair, Executive are partners by & the impact including today's available Worldwide Medical Vice Executive available We SEC GAAP presentation relationships. few slide the compounds to there available with and being to Chair where Pharmaceuticals. could COVID-XX financial Please today's investor.jnj.com. in non-GAAP at including note Joe
providing the to additional Moving The We remaining three last and conclude results will available position and commentary P&L XX guidance financial questions. time then your for cash allocation, XXXX results. quarter our updated before the webcast and capital to some agenda, provide business be with minutes. of anticipate the I and for today's will on up to and Joe sales will review segments. an third corporation overview the
reported was X.X%. by U.S., positively the sales of our the sales quarter outside XX.X% sales which XXXX, outside had U.S., growth an reported OUS a In X.X currency positive impacting third Now let's the billion Operational of growth, XXXX. increased quarter of points our move the Operational for increase regions $XX.X currency, U.S. translational X.X% growth to as sales X.X third was In the quarter impact currency effect the results excludes of XX.X%. versus third results. with Worldwide of increased points. were XX.X% the
sales operational adjusted divestitures, the and acquisitions of and XX.X% outside growth impact worldwide, U.S. X% U.S. the in was net XX.X% the Excluding
per was diluted the earnings earnings, and billion now $X.XX diluted were for quarter, versus Turning ago. earnings earnings $X.XX net a per year $X.X share to share of
special now and the sales quarter therefore, in the third upon worldwide currency stated, translation. for XXXX. and compared unless business for share adjusted side periods, expense increases growth you, have to the respectively percentage of billion items adjusted of both XX.X%. to $X U.S. XXXX an Excluding third sales per operational $X.XX, net billion of earnings I you segment otherwise increased adjusted outside X.X% quoted, per that front increased items of comparison diluted the impact X.X% were in and exclude after-tax highlighting build operational U.S. intangible quarter of change $X.X is diluted of was the of growth of the the consumer amortization performance, Beginning XX.X% share in with quarter basis, On earnings the XX.X% on asset health, will and representing earnings sales comment with and health of consumer represent X.X%
the was divestitures, of Excluding impact growth X.X%. worldwide
is to and of strong the relief that sales an demand increased of consumer for Motrin quarter. globally. pediatric increase When globally COVID-XX, operationally gains to the grew Although in performing and medicines Over-the-counter of growth variability due along business franchises fever portfolio saw XX.X% comparing in XXXX, to due drove vaccination well. U.S., health there the of the is the share overall impact with across X% the approximately Tylenol incidences symptom
cough, in flu, comparisons, outside as Additionally, benefited Sales category prior-year U.S. and Health from such in IMODIUM. China. reduction cold, recovery prior-year the increased brand specifically consumption Digestive demand for
divestiture impact Our franchise Pacific. to of of by basis Sedona, salon-based beauty due the in largely skin health of X% Asia declined globally, [Indiscernible] the portion the XXX point
XXX by approximately worth basis partially lost X.X% the driven Care market sun sales moisturizing Oral COVID-XX facial supply and of body to experienced driven modest care growth, aerosol constraints the the points. external this by performance globally, NEUTROGENA growth and largely impact, recall. impact and from and strong declined by in recovery e-commerce Excluding franchise due AVEENO offset divestitures
U.S. The to prior-year external comparisons Excluding for in promotions franchise COVID-XX this impact, due the in ability. globally, fighting impacts care category negative the franchise lockdowns baby and germ strong offset performance growth X.X% Listerine's from declined behind by and related U.S. by mostly with driven pressure, by along declined building e-commerce COVID-XX partially performance, offset and to the Asia-Pacific brand in Listerine competitive EMEA, and Asia-Pacific, Aveeno strong strong supply in constraints resulting
stocking franchise by Health due Women's to driven X.X% Asia-Pacific. grew globally, comparisons finally, prior-year U.S. in in declined And primarily to impacts. the Our X.X% our Care and globally, COVID-XX competitive franchise Wound pressure unfavorable prior-year lapping
the XX.X% our U.S. outside the XX.X% of segment. Moving Worldwide sales with Pharmaceutical and to U.S. of growth billion of in XX.X% increased of $XX on Pharmaceutical growth
divestitures, net and XX.X%. of impact worldwide growth acquisitions was the Excluding
roughly basis a by QX brands. reminder, points key access-related as comparison total across due resulting a was in XXX Additionally, to XXXX for of purposes, negatively in constraints decrease of impacted COVID-XX,
strong performance continued in market U.S. continued growth of quarter, and STELARA to all growth growing of Our continued and globally. nearly another of the share and as in penetration over of The to EU, continued formulation and TREMFYA, strong double-digit in with growth in positive double-digit in at U.S. due market delivered seven growth launches brand's DARZALEX delivered new and points patient market immunology points of but by COVID-XX offset X.X% impact the at losses of DARZALEX psoriasis alone all growth temporary quarter XX.X%. gains share roughly position, and of across X with sort U.S. share and the increased continued competition. X to disease grew in share over growth the psoriatic strong IMBRUVICA performance portfolio globally to show X increased U.S. points and increased operational of by the X its by above-market the XX.X% metastatic capabilities nearly lines gains, additional share due sales leading global across X products driven in declines in XX.X% in modest subcutaneous points growth XX.X%, portfolio the continue of colitis of indications enable also with indication. with remains up offset U.S. the commercial share due and points grew strength partially starts. levels. XX.X% double-digit which driven regions, in share adjusted REMICADE growth an worldwide penetration XX.X% on deliver in by that global to by Crohn's quarter, the to with TREMFYA indication. share was into share due led nearly gains, in a uptake Oncology arthritis quarter, U.S. biosimilar to points global example. the was the all this driven its also driven global in by us therapy STELARA growth strong arthritis. ERLEADA by constrained by psoriatic sales market all
of been patient the worldwide other at year-to-date persistency basis long-acting from XX.X% sales first penetration growth with posting the and driven bringing growth the medical competitive strong billion market outside UPTRAVI globally, and a quarter by INVOKANA biosimilar growth XX.X%, adjustment the Worldwide XX.X% total U.S. and worth I'll the has Pulmonary a gains. globally impacted attention The growth declined turn recorded U.S. revenue grew hypertension in cardiovascular, starts contribution included increased and for medical and of IMBRUVICA And and to your the growth. competition negatively of a In X.X% Neuroscience pressures devices million by to business of X the metabolism, portfolio, of XXX months XXX and addition, the $X.X growth $X.XX. sales vaccine, segment. of by not-for-profit achieved due of on million. now and U.S. year, global devices was paliperidone in nearly strong X% in to due of X.X% to by XX.X% price both XX.X% share OPSUMIT the of was U.S. Through PROCRIT. lastly, period driven growth in $XXX increased growth the COVID-XX new prior share that points market driven
of within China new XX.X% we of neurovascular, both recovering certain quarter, and expansion quarter continuing biosurgicals, sales impacted last market in of continued primarily procedures. at impact product quarter market expansion commercial such to communicated with introductions, reached lag and as most have milestone Worldwide grew who delivered XX.X% Orthopedics approach and introduced of for grew navigation, seen categories VELYS in China Endo prefer navigation. the procedures, this FIBULINK. the anterior Endo guidance In continued in we headless procedure like and surgeons growth. robotic the driven offset and and stem, new impact growth surgery grew partially anterior in outside driven Results ATTUNE and franchise MONARCH of which the by globally, the globally, and in compression from international COVID-XX of procedures the quarter, driven the to over cannulated in double-digit growth recovery by deemed segment, a approach and markets factors marketplace recovery, new the Orthopedics recovery. Closure grew enabling declines especially advanced the channel reflecting U.S. of U.S. market related the by driven X Solutions Results cutters, X.X% Asia Pacific. another execution. and outpatient tender and in reflect X.X% spine Hips to increase now on nature, primarily commercial outside grew of hip PINNACLE franchise capability X.X% leadership within introductions and by Needs the electrophysiology XX,XXX global Robotic-Assisted competitive portfolio. Building elective timing products, such of driven procedures X.X% approximately devices by worldwide significant worldwide nailing XX.X%, variant across suture of benefited the global X.X% as as of the momentum screws, by VELYS barbed Advanced the surgery divestitures, another XXX procedure offset grew Surgery approach. recovery and we products, success in from more new femoral General recently recovery Solution dual the Worldwide in orders robust COVID-XX be hip in mixed points by with and participate X.X% X procedures bronchoscopy declined traditional market continued The products on our energy, recovery, launched X.X%. growth we posterior Growth U.S. largest Delta U.S., strong the In Tier portfolio knees X.X% dynamics and procedure our the U.S. image the QX, competitive recent continued X quarter X recovery, is cutters VELYS the outside reflecting recovery OUS X.X% of of across in product was The success both Interventional which globally, pressure with in terms volumes in Excluding the increase market and worth medical and our supported U.S. Surgery our Tier growth. U.S. growth positive and impact also hospital by mobility X.X% hospital quarter, systems expansion, Trauma the of including Wound ACTIS basis energy and within achievement, contributor globally. addition support in and markets. partially the
as MULTIFOCAL, competitiveness, global portfolio, primarily momentum initiatives, of Orthopedics, procedure our growth FRESH. a positive success primarily franchise within The impact commercial volume including worth by COVID-XX. and a of Synergy. and by includes grew OASYS year of Lastly, ACUVUE XX.X% launched recovery, and products in enhanced growth XX% all by of of XX driven recovery to market related recently this initiatives, delivered regions continuing in products The and DEFINE ACUVUE quarter, new driving products about declined success TECNIS Worldwide lens continued X.X% Surgical market-leading the enhance launched reflects Spine XX% driven vision deceleration for recently competitiveness. ACUVUE global globally, market of and commercial X.X% across Eyhance such stocking driven prior U.S. Contact to negative decline points. TECNIS Vision
of that related year. consolidated Now, Cost driven I'd favorable XXX by changed the like highlight to quarter products last for mix statement points, a noteworthy of few same Pharmaceuticals. regarding compared COVID-XX quarter and sold recovery by earnings items our of growth improved to XXXX, third in the prior-year from basis of enterprise have impacts from
In versus and invest levels, strategically of to Auris. This Research and at investing increase with continue Development due year $X.X a portfolio the a development assets for of competitive $XXX XX.X% was quarter. of research prior the acquisition We partial million process investment progression. to billion sales XX.X% expense associated reflects in impairment this
The charges. other of the details due the to third billion Joe litigation-related expense a both in billion charges. net $X.X an XXXX, third quarter XXXX income of of from increase in R&D more and will expense on expense changed and line litigation-related $X.X of to net the in IP primarily quarter provide
third current tax of tax in the reserves of from rate our filing special income Along taxes matters. driven rate our was with XXXX Regarding the quarter, lower unfavorable I to in by For on one-time X.X% special in effective XX-Q basis, the on to versus items. period the review and driven compared a GAAP jurisdictions mostly details third and XX.X% XX.X% higher same year, in the tax upcoming the effective excluding positions quarter last items, quarter encourage by which XX% year. tax XXXX, quarter reoccur. third prior specific did not tax you additional quarter was
our earnings, of and have amortization income impact per slide, also intangible provided share your special adjusted the I'll boxed Lastly, and tax, we before earnings direct section to the exclude of to attention expense the items. where net
from adjusted margin let's Devices for driven between from XX.X%, before at margins quarter progression. segment. COVID-XX look the In fairly and to overall to XX.X% the development prior-year by leveraging to declined sales recovery. changes percentage of our from investment driven enable impacts sales improved prior income as Pharmaceutical Medical adjusted of third portfolio segments. with to XX.X% by expense a research XXXX, XX.X% by and tax related from Now income remained enterprise our resulting recovery consistent tax the year X some before
to by and Quarter driven COGS XXXX portion the earnings margins I'm item marketing one-time and health brand pleased That the partially XX.X% Third Wolk. improvement. Johnson sales to from turn Johnson concludes expenses over a to of Finally, increased & XX.X%, by consumer the offset declined now results. Joe call
